These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30551545)

  • 1. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats.
    Oraby MA; El-Yamany MF; Safar MM; Assaf N; Ghoneim HA
    Biomed Pharmacother; 2019 Jan; 109():910-920. PubMed ID: 30551545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amelioration of Early Markers of Diabetic Nephropathy by Linagliptin in Fructose-Streptozotocin-Induced Type 2 Diabetic Rats.
    Oraby MA; El-Yamany MF; Safar MM; Assaf N; Ghoneim HA
    Nephron; 2019; 141(4):273-286. PubMed ID: 30699409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
    Nørgaard SA; Briand F; Sand FW; Galsgaard ED; Søndergaard H; Sørensen DB; Sulpice T
    Eur J Pharmacol; 2019 Oct; 860():172537. PubMed ID: 31310751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced
    Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation.
    Hazem RM; Ibrahim AZ; Ali DA; Moustafa YM
    Int Immunopharmacol; 2022 Mar; 104():108503. PubMed ID: 34998036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
    Baer PC; Koch B; Freitag J; Schubert R; Geiger H
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis.
    Elkazzaz SK; Khodeer DM; El Fayoumi HM; Moustafa YM
    Life Sci; 2021 Sep; 280():119018. PubMed ID: 33549594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
    Abdel-Wahab AF; Bamagous GA; Al-Harizy RM; ElSawy NA; Shahzad N; Ibrahim IA; Ghamdi SSA
    Biomed Pharmacother; 2018 Jul; 103():59-66. PubMed ID: 29635129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.
    Tang L; Wu Y; Tian M; Sjöström CD; Johansson U; Peng XR; Smith DM; Huang Y
    Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E563-E576. PubMed ID: 28811292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model.
    Yang M; Shi FH; Liu W; Zhang MC; Feng RL; Qian C; Liu W; Ma J
    Front Endocrinol (Lausanne); 2020; 11():635. PubMed ID: 33312157
    [No Abstract]   [Full Text] [Related]  

  • 12. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
    Tanday N; Irwin N; Flatt PR; Moffett RC
    Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
    Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
    Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
    Dekkers CCJ; Petrykiv S; Laverman GD; Cherney DZ; Gansevoort RT; Heerspink HJL
    Diabetes Obes Metab; 2018 Aug; 20(8):1988-1993. PubMed ID: 29573529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
    Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
    PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of arctiin on glomerular filtration barrier damage in STZ-induced diabetic nephropathy rats.
    Ma ST; Liu DL; Deng JJ; Niu R; Liu RB
    Phytother Res; 2013 Oct; 27(10):1474-80. PubMed ID: 23147865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak LO; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Diabetes Obes Metab; 2018 Nov; 20(11):2617-2626. PubMed ID: 29923295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats.
    Mahfoz AM; El-Latif HA; Ahmed LA; Hassanein NM; Shoka AA
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1315-1324. PubMed ID: 27612855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction.
    Ahmed AS; Mona MM; Abdel-Kareem MA; Elsisy RA
    Biomed Pharmacother; 2021 Jul; 139():111624. PubMed ID: 33915503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.